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Summary 
SWR/J transgenic (tg) mice were generated expressing the TCR ~ chain derived from an anti- 
collagen type II (CII) arthritogenic T  cell clone. The SWR/J strain was selected because it is 
resistant to collagen-induced arthritis (CIA) and lacks the V/3 gene segment used by the T cell 
done. Expression of the tg/3 chain on all thymocytes and peripheral lymph node T  cells led 
to a more efficient anti-CII immune response, but did not confer CIA susceptibility to SWR/J 
mice. Nevertheless,  this tg/3 chain enhanced predisposition to CIA as (DBA/1  x  SWR) F1 
tg mice were more susceptible than normal F1 littermates. Our results demonstrate that the 
expression of the tg/3 chain contributes to CIA susceptibility,  but by itself it is not sufficient 
to overcome CIA resistance  in the SWR/J strain. 
C 
ollagen-induced arthritis  (CIA)  1 develops  in  certain 
strains of mice, rats, and primates after immunization 
with native type II collagen (CII) in CFA (1-3).  The disease 
can be induced by homologous as well as heterologous CII. 
Cyanogen bromide digestion of chicken CII gives rise to a 
major immunogenic and arthritogenic fraction which is rep- 
resented by the CBll peptide (4). Both antibody and T cell 
responses induced by heterologous CII immunization are pre- 
dominantly directed to epitopes that are present in the CB11 
peptide (5,  6). 
In mice, susceptibility to the disease is associated with the 
expression of particular MHC class II alleles such as Aq and 
A'  (7,  8).  Several polymorphic genes  at  other  loci  also 
influence disease susceptibility. The most extensively studied 
ones are genes encoding complement component C5, TCR 
chain, and Mls antigens (9-12). Several investigators have 
attempted to clarify the putative role of C5 in susceptibility 
to CIA. The results are difficult to interpret and are in part 
contradictory (9-11). 
The  crucial  role  of T  cells  in  CIA  has  been  dearly 
documented in many studies (13). The disease can be trans- 
ferred by T cells, either using cells fleshly isolated from CII- 
immunized animals or using CII-specific  Th cell lines and 
clones  (14-16).  Furthermore,  CIA  development  can  be 
prevented by injections ofmAb directed against the CD4 and 
1 Abbreviations used in this paper: BCG, Bacillus Calmette-Gu*rin; CIA, 
collagen-induced arthritis; CII, collagen type II; tg, transgenic. 
TCR molecules (17-19). Because of the linkage to particular 
class II alleles, one would expect that the "pathogenic T cells" 
may express a rather restricted TCR repertoire. Indeed, sev- 
eral  findings suggest that  the recognition of the disease- 
inducing CII epitope(s) requires particular TCR B chains. 
Mice  with  the  susceptible  H-2  background, but  with  a 
genomic deletion of certain TCR V/~ gene segments, are resis- 
tant to the induction of CIA. These mouse strains  have a 
deletion encompassing the V~9, V~11, V~12, V~13, V~5, 
and V~8 gene families, and have been classified as VB  ~ mu- 
tants (20,  21). Among these,  SWR/J and AU/SSJ strains, 
both of the H-2q haplotype, are CIA resistant (22, 23). Also, 
Rill S/J mice, which have an even larger deletion including 
Vfl6, Vf115, and Vf117 genes (Vfl  c mutants), are CIA resis- 
tant despite being H-2  r (24). The correlation between resis- 
tance to the disease and deletion of certain Vfl genes sug- 
gests that these genes play a role in the pathogenesis of CIA. 
Although this hypothesis is supported by gene complemen- 
tation and segregation experiments, the Vfl involvement in 
the control of CIA remains controversial  (9-11,  22). 
Recent studies on CIA in Mls-1 congenic mouse strains 
suggest that expression of a particular endogenous superan- 
tigen, Mls-P, results in decreased CIA incidence (12). En- 
dogenous superantigens are characterized by their ability to 
be recognized by subsets of T  lymphocytes bearing partic- 
ular Vfl chains. Expression of the superantigen in the thymus 
of mice with a permissive H-2, results in clonal deletion of 
the T  cells reactive to this superantigen. The consequence 
of the elimination of these autoreactive T  cells is tolerance 
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pression of Mls antigens may cause important ddetions in 
the V~ peripheral repertoire affecting T  cells that are pos- 
sibly important in the pathogenesis of the disease. 
The TCR V~ involvement in the pathogenesis of arthritic 
disease was also proposed upon analysis of TCR genes ex- 
pressed in T lymphocytes present in the synovia of rheuma- 
toid arthritis patients. In some (27-29), but not all of these 
studies (30-32), an expansion of oligoclonal T calls, or a re- 
stricted use of certain V~ chains (33,  34)  was observed. 
In the present study we have analyzed the role of TCR 
V~ genes in CIA using a different approach, namely by gener- 
ating SWR/J mice that are transgenic (tg) for a TCR/3 gene 
derived from an anti-CII arthritogenic T cell done. The par- 
ticular T  cell clone that we have used transfers  the disease 
and expresses a V~ region normally absent in the genome 
of the CIA-resistant strain, SWR/J (22). The tg SWR mice 
express the tg ~  chain on all T  lymphocytes, and after CII 
immunization, show increased T cell-dependent anti-CII an- 
tibody responses, but do not develop CIA. However, introduc- 
tion of the transgene into susceptible (DBA/1  x  SWR/J)F1 
mice clearly increases CIA predisposition. 
Materiak and Methods 
Mice.  DBA/1J,  SWR/J, and MORO/Ibm mice were obtained 
from Biological  Research Laboratories, (F~illinsdorf,  Switzerland). 
Transgenic mice were also  bred and maintained in the mouse colony 
at Hoffraann-La  Roche (Basal, Switzerland). F1 crosses were made 
between SWR/J male mice heterozygous for the B transgene and 
DBA/1J female mice. For immunofluorescence analyses, unim- 
munized mice were killed at 4-8 wk of age and CII immunized 
at day 42 after immunization. 
T Cells and Culture Conditions.  Ceils  were grown in IMDM 
(Gibeo, Paisley,  UK) supplemented  with 10% heat-inactivated  FCS 
(Flow, UK),  2 mM 1,glutamine, 1 mM Na pyruvate (Gibco), 5 
x  10 -s M 2-ME (Sigma Chemical Co., St. Louis, MO), 50 U/m1 
penicillin, 50 ~g/ml streptomycin, 100/~g/ml kanamycin  (Gibco), 
and incubated in a humidified incubator with 5% CO2. The anti- 
CII T cell clone K-102 was derived from the anti-CII T cell line 
previously  described  by Kakimoto et al. (15). The clone was charac- 
terized with respect to antigen specificity  and shown to passively 
transfer arthritis in DBA/1 recipients (K. Kakimoto, unpublished 
results). K-102 cells (2  x  10Vml)  were stimulated with 40/~g/ml 
human CII in the presence of 107/ml DBA/1 irradiated (3,000 tad) 
spleen ceils. Between stimulations, cells were maintained in cul- 
ture medium supplemented  with 10% supernatant of  Con A-stimu- 
lated rat spleen cells and 2 rag/m1 methyl o~-o-mannopyranoside 
(Sigma Chemical Co.) (35). 10 d after CII stimulation, blasts were 
purified over a ficoll gradient (Cederlane, Hornby, Canada) and 
fused with a subclone of BW-1100.129.237 ol-B- lymphoma cells 
(36). T cell hybridomas were obtained after HAT selection, sub- 
cloned, and analyzed for antigen specificity, and CD3 and CD4 
expression. 
Collagens and Preparations of cyanogen bromide (CNBr) Digests of 
CIL  Human and mouse type II collagens  were purified  from costal 
and sternal cartilages according to the method described  by Miller 
et al. (37). The purity of CII was assessed by SDS-PAGE. Bovine 
CII was a kind gift from M. J. Mullqeen and D. Bradshaw (Roche 
Products, Welwyn Garden City, UK). Chicken CII was purchased 
from Genzyme Corp. (Boston, MA), bovine type I, human type 
III, and human type IV collagens were all purchased from Sigma 
Chemical Co. Bovine and chicken CII were digested with CNBr 
in 70% formic acid at 37~  After desalting on a Sephadex G10 
column in 0.1 M acetic  acid, the digest was applied to a S-Sepharose 
column (Pharmacia, Uppsala, Sweden) equilibrated in 20 mM ci- 
trate, 20 mM NaC1 pH 3.8 buffer, and eluted with a linear NaC1 
gradient (20-500 mM). The temperature of the column was main- 
tained at 45~  Fractions containing stimulator), activity in the 
functional assay  (see below) were pooled, lyophilized,  and subjected 
to gel filtration chromatography  in PBS on a TSK 3000SW prepara- 
tive column (LKB-Pharmacia,  Gaithersburg, MD). The purity of 
the ehted peptides was checked  by SDS-PAGE according  to Laemmli 
(38), using a mini-gel system (Bio-Rad Laboratories, Richmond, 
CA). Partial amino acid sequences were determined on a protein 
sequencer (475 A; Applied Biosystems, Inc., Foster City, CA). 
Antigen-specific 11.,2 Release  Assay.  The T cell hybridoma (5 x 
104 cells/well) was tested with a titration  of collagens or CII 
CNBr peptides in the presence of DBA/1 or SWR/J spleen cells 
(5  x  10  s cells/well) in flat-bottomed 96-well plates (Costar, Cam- 
bridge, MA). After 20-24 h of incubation, cell-free supernatants 
were collected  and tested for I1,2 content using the CTL1,2 prolifer- 
ation assay. CTL1,2 were plated at 5  x  103/well, and after 20- 
24 h of culture were pulsed for an additional 6 h with 1/~Ci/well 
of [3H]thymidine (Amersham International,  Amersham, Bucks 
UK). Incorporated radioactivity was measured with a liquid scin- 
tillation B counter (Betaplate; LKB-Wallac, Turku, Finland) and 
is expressed as mean cpm of triplicate cultures. 
Induction and Evaluation of CIA.  Mice (8-10 wk) were im- 
munized by intradermal injection in the back at the base of the 
tail with 200/~g of  bovine or chicken CII in CFA (Difco Laborato- 
ries, Detroit, Michigan). An intraperitoneal injection of Mycobac- 
terium bovis Bacillus Calmette-Gu6rin (BCG, ,,o0.8-2.6  x  106 
cells/mouse; Schweiz. Serum- & Impfmstitut, Bern, Switzerland) 
was also given to the mice at the same time. 21 d after the immuni- 
zation, mice were boosted intraperitoneally with 200 #g of CII 
together with BCG. Arthritis was monitored daily from day 21 
until day 35, weekly during the second month, and then every 
2 wk thereafter. Mice were monitored for up to 3 mo, and in the 
case ofSWR fl tg mice, for up to 5 mo after immunization. Dates 
of onset of disease were recorded for individual mice. CIA was di- 
agnosed if redness and swelling of fore- and hindpaws were ob- 
served. Severity  of arthritis was evaluated  for each paw and graded 
as following: grade 1, redness and swelling; grade 2, deformity; 
and grade 3, ankylosis.  The scores for each paw were added to give 
an index ranging from 0 to 12 per mouse. None of the mice ever 
developed CIA after CFA/BCG injection. Statistical analysis was 
done using the X  2 test (for comparing CIA incidence) and the 
Mann-Whitney test (for comparing day of onset and severity of 
CIA). 
TCR 3 Gene Construct and Generation of SWR ~ tg Mice.  The 
productively rearranged TCR B gene has been isolated by PCR 
amplification from genomic DNA of the anti-CII T cell clone. 
Primers used are complementary to sequences located in the 5' 
flanking region of the VB12 leader sequence containing an addi- 
tional SalI cloning site (5' primer), and in the intron between JB1.2 
and JB1.30' primer), allowing the amplification  of a DNA region 
containing a BamHI site at the 3' ofJB1.2, pCR was performed 
for 35 cycles (94~  40 s; 65~  50 s; and 72~  60 s) followed 
by 5 rain at 72~  using Taq DNA polymerase  (Perkin-Elmer  Cetus, 
Emeryville, CA). The amplified  fragment of ~900 bp was inserted 
into a plasmid vector containing TCR B enhancer and VB8.3 pro- 
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land). A 6.4-kb fragment  spanning the region from the BamHI 
site located in the J/31 locus to the HindlII site at the end of the 
C/31 untranslated  region,  was further  ligated into the construct 
at the corresponding  BamHI site (see Fig. 2). This provides the 
entire C/31 region used by the K-102 T cell clone. After DNA se- 
quencing to control possible PCK and ligation artifacts, the/3 con- 
struct was excised from  the prokaryotic  vector  (pBluescript  II 
KS- ; Stratagene, La Jolla,  CA) by digestion with BssHII,  sepa- 
rated on agarose gd, and purified by phenol/chloroform  extrac- 
tions followed by ethanol precipitation. Transgenic mice were gener- 
ated by microinjection of the purified DNA into SWR/J fertilized 
oocytes that were reimplanted into the oviducts of MOP,  O/Ibm 
foster mothers as described (39). The integration  of the transgene 
was analyzed both by PCR and Southern blot using DNA isolated 
from tail biopsies of 2-3-wk-old mice. The transcription of the full- 
length tg B RNA was demonstrated by Northern blot using total 
spleen RNA. 
Antibodies andFlow Cytometry.  The following mAb were used: 
anti-CD3 e biotin-conjugated  (500A2; PharMingen,  San Diego, 
CA) or FITC-conjugated (145-2Cll; Boehringer Mannheim, Mann- 
helm, Germany); anti-CD4 PE-conjugated (GK1.5; Becton Dick- 
inson & Co., Mountain  View, CA); anti-CD8  FITC-conjugated 
(53-6.7; Becton Dickinson & Co.); anti-Thy 1.2 FITC-conjugated 
(30-H12; Becton Dickinson  & Co.);  anti-VB2 (B20.6.5,  kindly 
provided  by B.  Malissen, MarseiUe-Luminy, France); anti-V~3 
(KJ25a; J. Kappler, Howard Hughes Medical Institute, Denver, CO); 
anti-VB4 (KT4-3; K. Tomonari, Medical Research Coundl, Harrow, 
U.K.);  anti-V~6  (44-22-1; H.  Hengartner,  University  Hospital, 
Ziirich, Switzerland); anti-V~8.1, 8.2, and 8.3 (U. Staerz, National 
Jewish Center, Denver, CO); anti-VBll (KT11; K. Tomonari); and 
anti-V~17a (KJ23a, J. Kappler) were all used as cell culture super- 
natants.  The MR11-1  hybridoma  secreting anti-V/312 mAb was 
produced by O. Kanagawa (Washington University, St. Louis, MO), 
and obtained through the courtesy of H. R. MacDonald (Ludwig 
Institute for Cancer Research, Lausanne, Switzerland).  The anti- 
body was purified from the cell culture supernatant and biotinylated 
by standard procedures using N-bydroxysuccinimidobiotin  (Sigma 
Chemical  Co.).  Second  step  reagents  were:  sheep  anti-mouse 
Ig-FITC,  and sheep anti-rat  Ig-FITC (Silenus, Hawthorn, Aus- 
tralia); goat anti-mouse Ig-PE, and goat anti-rat Ig-PE (Southern 
Biotechnology Associates, Birmingham, AL); and streptavidin-FITC 
or streptavidin-conjugated tandem label of PE/Texas Red (Southern 
Biotechnology Associates). All incubations and washings were done 
at 4~  in PBS, 2% FCS, 0.02% NAN3. 20,000 or 50,000 viable 
cells were analyzed by FACScan  |  (Becton Dickinson & Co.). Dead 
cells were excluded from the analysis using forward and side scatter 
parameters and also using propidium  iodide when possible. 
Serum Anti-CII Antibody Levels.  ELISA  was  performed  as 
follows: fiat-bottomed  Maxi Sorp 96-well Immuno Plates (Nunc, 
Roskilde, Denmark) were coated overnight at 4"C with 50/~l/well 
of either CII or purified protein derivative from Mycobacterium tuber- 
culosis (PPD, Statens Seruminstitut,  Copenhagen, Denmark),  BSA 
(Sigma Chemical Co.), or goat anti-mouse Ig (Southern Biotech- 
nology Associates), all at 10/zg/ml. Plates were saturated with 1% 
BSA in PBS, and after washing,  sera were added at various dilu- 
tions. After five washes with PBS, 0.05% Tween 20, ~ galactosidase- 
hbeled antibodies (anti-mouse Ig, IgM, IgG1, IgG2a, IgG2b, IgG3, 
Southern Biotechnology Associates) were added and incubated over- 
night at 4~  Positive wells were revealed with O-nitrophenyl-~- 
n-galactopyranoside (Sigma Chemical Co.) and ODium was de- 
termined using a microplate reader (Anthos  Labtec, Basel, Swit- 
zerland). 
Results 
The T Cell Hybridoma BL17 Recognizes the CBlI Fragment 
of CII.  A  T  cdl hybridoma, BL17, was derived from the 
fusion of the arthritogenic anti-CII T  cell done K-102 and 
the BW-1100.129.237  c~-~- T cell lymphoma (see Materials 
and Methods). This hybridoma expresses high levels of CD3 
and CD4. Stimulation by immobilized anti-c~/~ TCR or anti- 
CD3 antibodies leads to Ib2 release and apoptosis (data not 
shown). Like the parental clone, the hybridoma produces Ib2 
in  response  to  bovine,  chicken,  human,  and  mouse  CII 
presented by DBA/1  APC (data not  shown). 
To further characterize the antigen specificity,  bovine and 
chicken CII were digested with CNBr, and the peptides were 
fractionated by ion exchange and gel filtration chromatog- 
raphy.  The fractions were tested for their ability to induce 
Ib2 release in the presence of APC. Stimulatory activity could 
be attributed to a peptide migrating with an apparent mo- 
lecular mass of about 36 kD on SDS-PAGE (data not shown). 
Partial amino acid sequences of the stimuhtory peptides from 
both bovine and chicken CII showed that they were identical 
with the previously described CBll peptide (40), a 279-amino 
acid-long peptide that is the main CII fragment recognized 
by both  antibodies and T  ceils  in mice with  CIA. 
$ WR/J  Spleen Cells Can Process and Present CII and its CB11 
Fragment to the T Cell Hybridoma.  SWR/J mice are not sus- 
ceptible to CIA induction,  perhaps because of the deletion 
of some V~ gene segments. An alternative explanation could 
be that although they carry susceptibility-associated  H-2 genes, 
their APC might be unable to present arthritogenic CII epi- 
topes. We have excluded this possibility by showing that spleen 
cells from SWR/J mice are able to process and present either 
bovine, chicken and human  CII  (Fig.  1 a),  or bovine and 
chicken CBll  (Fig.  1 b) to the BL17 hybridoma. 
Thus,  the resistance of SWR/J to CIA is not due to a 
defect in antigen  presentation. 
Generation of TCR B Transgenic Mice.  We have attempted 
to sensitize the SWR mice to CIA by introducing  a trans- 
gene encoding the BL17 TCR ~  chain.  This TCR B chain 
was shown to be encoded by V/512-D~l.l-J~l.1  and C~/1 
(L. Mori, unpublished results). The productively rearranged 
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Figure 1.  Antigen  presentation by SWR/J spleen cells. BL17  cells  were 
stimulated by CII or its CBll fragment in the presence of SWR/J APC. 
The levels  oflb2 secreted  were measured  using the CTLL-2  assay. (a) Shows 
the stimulation with bovine CII (11), human CII (0), and chicken CII 
(A); (b) with bovine CB11 ([~) and chicken CB11 (A). Results are ex- 
pressed  as mean cpm of [3H]thymidine  incorporation of triplicate cultures. 
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Figure 2.  TCR ~ construct used for the generation of transgenic mice. 
The construct is composed of a PCR-amplified fragment that contains 
the leader sequence of VB12 (L), V~12, DBI.1, and JBI.1 (nucleotide se- 
quence  is available upon request).  This fragment is inserted 3' to the/3 
locus enhancer (E/3) and promoter (P) of V/iS.3, and 5' to the entire CB1 
lOCUS. 
TCK B gene was isolated by PCR amplification of genomic 
DNA isolated from the anti-CII T cell clone K-102, and in- 
serted into a plasmid vector containing the TCR/3 enhancer 
and VBS.3 promoter sequences. A fragment encompassing 
the entire C/51 locus was further inserted at the 3' end of 
the V/5 gene (Fig. 2). This TCK/5 construct, free from vector 
sequences, was used for the generation of tg mice. 
Two tg mouse lines were obtained in the SWK/J strain. 
All experiments described in this study were carried out with 
one of these lines (SWR-/SL tg) which integrated about 10 
copies of the transgene into the genome and expressed very 
high levels of tg/5 chain mRNA in the spleen  (data  not 
shown). 
Expression of the TCR /8 Transgene in the Absence of  Endoge- 
nous B Genes.  The expression of the TCR/5 transgene was 
tested using a mAb specific for the mouse V/512 polypeptide. 
Thymocytes and lymph node cells from tg mice and non-tg 
littermates were stained with mAb specific for CD4, CD8, 
and V/512, and evaluated by three-color FACS  |  analysis. 
In the thymus, V/512  + calls were undetectable in SWK 
mice, as expected, but were present in SWR-BL tg animals 
(Fig.  3, a and d). The number of V/512 + and CD3 * ceils 
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Figure 3.  Thymocyte surface expression of the transgenic/3 chain in 
SWR-BL tg mice. Thymocytcs from SWK-BL tg and non-tg, sex-matched, 
littermate mice were stained with anti-CD8 (FITC-conjugated), anti-CD4 
(PE-conjugated) and anti-V/~12 or anti-CD3 (biotin-conjugated), followed 
by labeling with streptavidin-tandem (see Materials and Methods). (a and 
d) Histograms of the Vf112 staining; (b and e) Histograms of the CD3 
staining; (c and  f) Contour plots for CD4 and CD8 stainings ofceUs gated 
as CD3 + . Numbers represent the percentage of cells in each region. The 
difference in staining of the TCR. k'~ population, using anti-Vf112 or anti- 
CD3, has to be attributed to different ai~nities  of the two mAb. 
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Figure 4.  Lymph node T cell surface expression of the transgenic/~ chain 
in SWR-BL tg mice. Total lymph node cells from SWR-BL tg and non- 
tg, sex-matched, littermate mice were analyzed by three-color staining as 
in Fig. 3. (a and d) Histograms of the V~12 staining; (b and e) Histo- 
grams of the CD3 staining; (c and f) Contour plots for CD4 and CD8 
stainings of cells gated as CD3 +. Numbers represent  the percentage  of 
cells in each region. 
was similar, thus indicating that every T  cell expresses the 
transgene. Although the total number of CD3 + thymocytes 
was similar in normal and tg animals, there were differences 
in the percentages of mature cells. Tg mice had a lower number 
of CD3  hi thymocytes (3% vs 12% in normal animals) and 
this was compensated by a higher number of immature, 
CDY  ~  cells  (49%  vs  45%;  Fig.  3,  b  and  e)  and 
CD3+CD4+CD8 + cells (63%  vs 53%; Fig.  3, c and f). 
In lymph nodes of tg mice all CD3 + cells were V/512  + 
and were reduced in number (52% vs 74% of total lymph 
node cells; Fig. 4, a, b, d, and e), but the ratio of CD4 to 
CD8 cells was as in normal mice (Fig.  4, c and f). 
We also used other VO-specific mAb (anti-VB 2, 3, 4, 6, 
and 17a) to show the lack of expression  of endogenous/3 
genes. Indeed, none of these reagents stained either thymo- 
cytes or lymph node cells in SWR-/SL tg animals (data not 
shown). 
These results show that the tg/~ chain is expressed on the 
surface of T cells and that it prevents the expression of the 
endogenous TCR/3 chains. Furthermore, expression of this 
chain also affects the number of mature cells, without al- 
tering the relative percentages of CD4 + and CD8 + subsets. 
SWR-~L  tg  Mice Mount  Strong Anti-CII Antibody  Re- 
sponses.  The antibody response of mice to CII is strictly T 
cell dependent (41). SWK/3 tg and non-tg littermates, as 
weU as DBA/1 mice were immunized with bovine CII in 
CFA. At different time points after immunization, mice were 
bled and the anti-CII antibodies were analyzed by ELISA. 
It is interesting that the SWR-BL tg mice produce more anti- 
CII antibodies (day 7 titer, 8; day 14 titer, 50; and day 21 
titer, 400) than DBA/1 mice (day 14 titer,  15, and day 21 
titer, 200) and SWR non-tg littermates (day 14 titer, 3, and 
day 21 titer,  25; Fig. 5). Furthermore, their response devel- 
oped earlier as compared with the other groups. Already at 
day 7 after immunization, SWR-/SL tg mice had detectable 
titers of anti-CII antibodies of the 3/1, 3'2b, and 3'2a isotypes. 
The anti-CII antibody titer in SWR-/SL tg mice was always 
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Figure 5.  Increase  in the total 
anti-CII antibody  titer in the pri- 
mary response of SWK-BL tg 
mice. Titration of the total anti- 
bovine  CII Ig present in the serum 
of mice immunized with bovine 
CII in CFA (open  symbols)  or only 
injected  with CFA (cbsed  symbols) 
on different days  after immuniza- 
tion:  SWR-/~L tg  ([],  I); 
SWR/J (A, a); DBA/1 (O, O). 
Each curve represents the values 
obtained from the pooled sera of 
three mice. Results are expressed 
in OD~nm. Control ELISA  with 
BSA-coated plates gave back- 
ground values ~0.172. 
higher than in SWR non-tg littciraates for all antibody dasses 
and at all  time points  (data not  shown). 
Thus, in the SWR-BL tg mice there seems to be an early 
switch  to  all  Ig  isotypes  and  in  particular  to  ~/2a that 
predominates in the anti-CII antibody response during CIA 
(41). This finding, together with the fact that the antibody 
titer is higher in the tg mice, suggests that these mice may 
have an increased number of CII-specific Th cells. 
SWR-~L tg Mice Are Resistant to CIA.  SWR-/~L tg mice 
were tested for the development of CIA, to determine whether 
the expression ofa Vf112 bearing TCR/3 chain on all T cells, 
and the increased production of anti-CII antibodies observed 
in these mice were sufficient to make them susceptible to the 
disease. A total of 31 SWIL-/~ tg mice and 27 SWR non-tg 
littermates were immunized with bovine CII in CFA in three 
separate experiments. 21 d after the immunization, mice were 
boosted with bovine CII and analyzed for the development 
Table  1.  SWR-~L tg Mice are Resistant to CIA 
Mice*  Arthritic/Total  Incidence 
% 
Experiment  1  SWK-BL tg  0/12  0 
SWR/J  0/14  0 
DBA/1  7/11  64 
Experiment  2  SWIL-/~L  tg  0/13  0 
SWR/J  0/8  0 
DBA/1  6/7  86 
Experiment  3  SWR-/3L  tg  0/6  0 
SWR/J  0/5  0 
DBA/1  4/5  80 
* Male and female mice were used. 
of arthritis.  As shown in Table 1, none of the SWK devel- 
oped clinical signs of CIA regardless of the presence of the 
transgene,  even 5 mo after the first injection.  In contrast, 
64-86%  of the DBA/1 mice showed clinical signs of CIA, 
starting  from day 21 to day 33 after CII immunization. 
Expression of the tg ~  Chain in Susceptible Mice Leads to In. 
creased Incidence and Severity of CIA.  Susceptibility to CIA 
is a dominant trait since (DBA/1  x  SWK) F1 mice develop 
CIA  (10,  11). Both  tg  and non-tg  F1 littermates,  derived 
from crossing SWK mice heterozygous for the/~  tg with 
DBA/1, were immunized with CII and observed for the de- 
velopment of CIA. Arthritis developed in 38% of (DBA/1 
x  SWK) F1 mice and in 89%  of the F1/3L tg mice in a 
total of three independent  experiments  (Table  2).  The dis- 
ease induced in F1 BL tg mice was more severe (median ar- 
thritic score 8 vs 4) and developed 2 d earlier than in F1 non- 
tg littermates.  V/312 was expressed in the tg mice by all T 
cells present in lymph nodes draining the affected limbs, as 
well as in the corresponding  lymph nodes of the tg mice 
without clinical CIA (Fig. 6). FACS  |  analysis  using other 
V/3-specific mAb (anti-V/3 2, 3, 4, 6, 8, 11, and 17a), showed 
that  none of the F1/~L tg animals  also expressed endoge- 
nous/3  genes (data not  shown). 
Table  2.  CIA in (DBA/1  x  SWR-ffL tg) F~ Mice 
Mice  Arthritic/Total  Incidence*  Day of onset**  Severity* *  * 
% 
F1/3L  tg littermates  25/28  89  26 (21-29)  8 (12-3) 
Ft non-tg littermates  8/21  38  28 (28-36)  4  (9-3) 
* p  <0.001. 
** Median values  (range), p  <0.01. 
"**  Median values  (range), p  <0.05. 
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Figure 6.  Lymph node T cell surface  expression of the transgenic fl chain 
in (DBA/1  x  SWK-BL tg) F1 mice. Total lymph node cells from Pl BL 
tg and non-tg, sex-matched, littermate mice were stained with anti-Vf112 
biotin-conjugated  followed by su~ptavidin-FITC  (a-c, g-,) or with anti- 
CD3 FITC-conjugated (d-f, j-I ) and analyzed by FACScan  |  (a, d, g, j) 
Histograms  of stained cells from mice before CII immunization; (b, e, 
h, k) Histograms of stained cells from CII-immunized  mice without clin- 
ical CIA at day 42; (c,f, i, 1  ) Histograms of stained  cells  from CII-immunized 
mice with clinical CIA at day 42. Numbers represent the percentage of 
calls in each region. 
These results indicate that the expression on all T cells of 
a TCR fl chain derived from an arthritogenic anti-CII T cell 
clone, increases susceptibility to CIA in prone (DBA/1  x 
SWR/J) FI mice, but does not confer susceptibility to resis- 
tant ones (SWR/J). 
Discussion 
Transgenic mice have been generated expressing the TCR 
fl chain derived from the arthritogenic anti-CII T cell clone 
K-102. The clone responds to CII of several animal species, 
including mouse, and recognizes CB11, which is the main 
arthritogenic CII peptide. DBA/1 mice that are injected with 
K-102 cells acquire a mild form of arthritis (K.  Kakimoto, 
unpublished results). 
For the generation oftg mice, we have chosen the SWR/J 
strain because it is resistant  to CIA and because it lacks the 
VB12 gene that is expressed by the T  cell done. 
TCR fl tg SWR mice express the tg/3 chain on the sur- 
face of immature double- and of mature single-positive thymo- 
cytes,  without any preference  for single CD4 + cells. All 
thymocytes express only the tg fl chain, which is in agree- 
ment with previous findings that showed that functionally 
rearranged TCR fl transgene prevents the expression of en- 
dogenous ~8 genes (42). In tg animals, the number of mature 
thymocytes that express high levds of TCR is reduced, as 
compared with thymocytes of normal SWR mice, but cells 
expressing low TCR levels are slightly increased. The reduc- 
tion in the number of mature orb cells in the B tg mice is 
probably due to the limitation in TCR repertoire generation. 
This limitation could result from the lack of expression of 
more than one fl chain, as well as from the failure of this 
chain to pair with certain c~ chains (43). 
Also, the T cells in peripheral lymph nodes of tg mice ex- 
pressed only the tg j8 chain, as demonstrated by immuno- 
fluorescence using anti-CD3, anti-Vf112, and a panel of anti- 
Vfl mAb. Despite the reduction in the TCR repertoire size 
and in the number of c~B + T  cells, tg mice did not show 
any obvious signs of immunodeficiency. They are capable of 
developing protective immune responses against viruses and 
bacteria to a similar extent as their non-tg littermates (data 
not shown). When immunized with CII, the tg mice de- 
velop immunity to CII as demonstrated in vitro by the isola- 
tion of CII-specific T cells (data not shown) and in vivo by 
the production of anti-CII antibodies of all IgG classes. Fur- 
thermore, the antibody responses develops faster in tg than 
in non-tg mice, presumably because of the increased number 
of CII-specific  Th cells. 
Despite the very effective anti-CII immune response, SWR- 
BL tg mice do not develop CIA after  CII immunization. 
Nevertheless,  we could demonstrate a role for the Vf112 tg 
chain in CIA as (DBA/1  x  SWR)  F1 ~-.  tg mice were 
dearly more susceptible than normal F1 littermates.  The de- 
vdopment of CIA in F1 ~L tg mice that do not express en- 
dogenous fl genes, rules out the possibility that T ceils bearing 
~/chains other than the tg fl chain are required for the initia- 
tion and/or the progression of the disease. 
Apparently, TCR B tg SWR mice lack other genes that 
are required for CIA susceptibility. What are these other genes? 
One possible candidate is the gene encoding the complement 
component C5. This gene is defective in SWR mice and its 
role in CIA remains controversial  (9-11).  Other candidate 
genes might be involved in antigen recognition and include 
the TCR cr genes and the antigen itself. Differences in an- 
tigen processing and presentation that might exist in different 
mouse strains do not seem to be relevant, as we have demon- 
strated that SWR cells process and present the arthritogenic 
CII epitope to the T  cdl hybridoma. The possibility exists 
that SWR mice express a CII allele whose product is not 
recognized by the T cell clone that we have used as a source 
of the transgene. Alternatively, we cannot exclude the possi- 
bility that SWR mice lack a particular Vc~ gene segment 
that is required for the generation of T  cells that cause ar- 
thritis, but not of Th cells involved in anti-CII antibody 
production. The generation of mice tg for both a  and B genes 
derived from the arthritogenic clone will address this point. 
In conclusion, our tg model has confirmed the importance 
386  Collagen-induced  Arthritis in TCR B Transgenic Mice of the TCK fl genes in the development of CIA, and has 
clearly shown that a tg B chain derived from an arthrito- 
genic T  cell clone can increase susceptibility to CIA. This 
tg model also indicates that other genes are involved in the 
pathogenesis of arthritis, thus adding CIA to the list of au- 
toimmune diseases with multiple genetic control. 
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